Search

everythinglearnresearchcommunity

for

Search:↓

Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.

Women with Female Pattern Hair Loss may experience more stress, anxiety, and depression, and have lower levels of BDNF, which could predict the psychological impact.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.

The AI system HairComb accurately scores hair loss severity, matching dermatologist assessments.

Triamcinolone is more effective than methotrexate for treating localized alopecia areata.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Combining antihistamines with topical treatment improves hair regrowth in alopecia areata.

Bimatoprost may help treat hair loss from alopecia areata.

Certain NK cell changes in blood may indicate alopecia areata progression.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Actinic keratosis is more common in older men with certain genetic traits, but smoking seems to reduce its odds.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Parental uveitis increases offspring's risk and severity of autoimmune eye disease.

Topical tofacitinib is effective and safe for treating alopecia areata.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

The conclusion is that proper diagnosis and long-term treatment, including medication, hair removal, and lifestyle changes, are important for improving hirsutism, especially in PCOS patients.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

The study concluded that different treatments reduced post-COVID symptoms over time and that factors like age, severity, and comorbidities affect symptom risk.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Certain KIR genes in Indian SLE patients are linked to disease severity and could be biomarkers.

Topical flutamide works as well as hydroquinone for melasma but needs more safety checks.

People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.